Cryo-Cell International (NYSEAMERICAN:CCEL) Share Price Crosses Below 200 Day Moving Average – Here’s What Happened

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.53 and traded as low as $3.42. Cryo-Cell International shares last traded at $3.45, with a volume of 2,075 shares traded.

Cryo-Cell International Trading Down 0.1%

The firm’s fifty day moving average price is $3.54 and its 200-day moving average price is $3.53. The company has a market cap of $28.17 million, a P/E ratio of -10.59 and a beta of 0.48.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $7.68 million during the quarter.

Institutional Trading of Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is currently owned by hedge funds and other institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.